{"id":2303,"date":"2024-07-27T13:09:21","date_gmt":"2024-07-27T11:09:21","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2303"},"modified":"2025-11-28T11:00:45","modified_gmt":"2025-11-28T10:00:45","slug":"az-influenza-elleni-vedooltasok-eredmenyessege-a-2022-2023-as-influenzaszezonban-europaban-a-h1n1pdm09-a-ah3n2-es-a-b-influenzatipusok-cirkulacioja-idejen-vebis-korhazi-vizsgalat","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2024\/07\/27\/az-influenza-elleni-vedooltasok-eredmenyessege-a-2022-2023-as-influenzaszezonban-europaban-a-h1n1pdm09-a-ah3n2-es-a-b-influenzatipusok-cirkulacioja-idejen-vebis-korhazi-vizsgalat\/","title":{"rendered":"Az influenza elleni v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9ge a 2022\/2023-as influenzaszezonban Eur\u00f3p\u00e1ban a (H1N1)pdm09, a A(H3N2) \u00e9s a B influenzat\u00edpusok cirkul\u00e1ci\u00f3ja idej\u00e9n \u2013 VEBIS* k\u00f3rh\u00e1zi vizsg\u00e1lat"},"content":{"rendered":"

A 2022\/2023-as influenzaszezonban (2022. okt\u00f3ber \u2013 2023. m\u00e1jus) Eur\u00f3p\u00e1ban v\u00e9gzett multicentrikus, k\u00f3rh\u00e1zi vizsg\u00e1latunkban az influenza elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get (VE) m\u00e9rt\u00fck a feln\u0151tt lakoss\u00e1g k\u00f6r\u00e9ben. A kutat\u00e1sban k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 18 \u00e9ves \u00e9s id\u0151sebb, feln\u0151tt p\u00e1cienseket vizsg\u00e1ltunk, akik megfeleltek a s\u00falyos, akut l\u00e9g\u00fati megbeteged\u00e9s klinikai krit\u00e9riumainak.<\/p>\n

Az eset-kontroll elrendez\u00e9s\u0171 vizsg\u00e1latot teszt-negat\u00edv m\u00f3dszerrel v\u00e9gezt\u00fck. Esetnek azokat a betegeket tekintett\u00fck, akikn\u00e9l az influenzav\u00edrus jelenl\u00e9t\u00e9t RT-PCR vizsg\u00e1lat igazolta, m\u00edg a kontrollcsoportba azok a p\u00e1ciensek ker\u00fcltek, akik azonos klinikai krit\u00e9riumok alapj\u00e1n ker\u00fcltek k\u00f3rh\u00e1zba, azonban influenza-PCR vizsg\u00e1latuk negat\u00edv eredm\u00e9nyt adott. Az eredm\u00e9nyeket \u00e9letkor, nem \u00e9s legal\u00e1bb egy fenn\u00e1ll\u00f3 kr\u00f3nikus betegs\u00e9g jelenl\u00e9te szerint korrig\u00e1ltuk.<\/p>\n

\u00d6sszesen 5547 f\u0151t vontunk a vizsg\u00e1latba, akik k\u00f6z\u00fcl 2963-an (53%) kapt\u00e1k meg az influenza elleni v\u00e9d\u0151olt\u00e1st. Az influenzav\u00edrus A(H1N1)pdm09 t\u00edpusa ellen m\u00e9rt VE az 11% volt, az A(H3N2) alt\u00edpus ellen 20%. Az influenza B v\u00edrus ellen az oltottak t\u00f6bb mint fel\u00e9n\u00e9l (56%) kialakult a v\u00e9detts\u00e9g.<\/p>\n

A 2022\/2023-as l\u00e9g\u00fati szezonban a s\u00falyos l\u00e9g\u00fati megbeteged\u00e9ssel k\u00f3rh\u00e1zba ker\u00fcl\u0151 p\u00e1ciensek k\u00f6z\u00f6tt az influenza B ellen m\u00e9rt\u00fck a legnagyobb v\u00e9detts\u00e9get. Az influenza A alt\u00edpusai ellen m\u00e9rt alacsonyabb v\u00e9detts\u00e9g ugyanakkor azt jelzi, hogy az eredm\u00e9nyekre \u00e9p\u00fcl\u0151 olt\u00f3anyag-fejleszt\u00e9s tov\u00e1bbra is kulcsfontoss\u00e1g\u00fa a megfelel\u0151 v\u00e9delem el\u00e9r\u00e9s\u00e9hez, k\u00fcl\u00f6n\u00f6sen a k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 betegek k\u00f6r\u00e9ben. Az eredm\u00e9nyek tov\u00e1bb\u00e1 r\u00e1vil\u00e1g\u00edtottak arra is, hogy a pontosabb VE becsl\u00e9sek \u00e9rdek\u00e9ben a k\u00f6vetkez\u0151 szezonokban t\u00f6bb oltott r\u00e9sztvev\u0151 p\u00e1ciens toborz\u00e1s\u00e1ra van sz\u00fcks\u00e9g.<\/p>\n

    \n
  1. \u00e1bra: A s\u00falyos akut l\u00e9g\u00fati megbeteged\u00e9sben (SARI) \u00e9rintett betegek sz\u00e1ma az eseti st\u00e1tusz szerint \u00e9s az olt\u00e1s vagy mintav\u00e9tel hete szerint, VEBIS k\u00f3rh\u00e1zi vizsg\u00e1lat, 2022\/2023-as influenzaszezon, Eur\u00f3pa (N = 5547)<\/strong><\/li>\n<\/ol>\n

    \"\"<\/p>\n

    Forr\u00e1s: Influenza Other Respir Viruses. 2024 Feb 25;18(2):e13255. doi: 10.1111\/irv.13255 publik\u00e1ci\u00f3 alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n


    \nVaccine effectiveness against influenza hospitalisation in adults during the 2022\/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network<\/strong><\/h3>\n

    Angela M C Rose <\/em>(Epiconcept, Paris, France)
    \nFrancisco Pozo <\/em>(National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.)
    \nGerg\u0151 T\u00fari <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
    \nKatalin Krisztalovics<\/em> (National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
    \nAnnam\u00e1ria Ferenczi<\/em> (National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
    \nKrisztina Mucs\u00e1nyin\u00e9 Juh\u00e1sz<\/em> (National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
    \nand the VEBIS SARI VE network team; Belgium SARI Surveillance Network (BelsariNet)<\/em><\/p>\n

    Abstract<\/strong><\/h5>\n

    We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022\/2023 influenza season in Europe. Among 5547 SARI patients \u226518 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022\/2023 season, while VE against hospitalisation with influenza B was >55%, it was \u226420% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.<\/p>\n

    * Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

    Rose AMC, Pozo F, Mart\u00ednez-Baz I, Mazagatos C, Bossuyt N, Cauchi JP, Petrovi\u0107 G, Loghin II, Vaikutyte R, Buda S, Machado A, Duffy R, Oroszi B, Howard J, Echeverria A, Andreu C, Barbezange C, D\u017eiugyt\u0117 A, Nonkovi\u0107 D, Popescu CP, Majauskaite F, Tolksdorf K, Gomez V, Domegan L, Horv\u00e1th JK, Castilla J, Garc\u00eda M, Demuyser T, Borg ML, Tabain I, Lazar M, Kubiliute I, D\u00fcrrwald R, Guiomar R, O’Donnell J, Krist\u00f3f K, Nicolay N, Bacci S, Kissling E; VEBIS SARI VE network team; Belgium SARI Surveillance Network (BelsariNet). Vaccine effectiveness against influenza hospitalisation in adults during the 2022\/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Influenza Other Respir Viruses. 2024 Feb;18(2):e13255. doi: 10.1111\/irv.13255. PMID: 38403302; PMCID: PMC10894713.<\/span><\/p>\n

    https:\/\/pubmed.ncbi.nlm.nih.gov\/38403302\/\u00a0<\/strong><\/a><\/p>\n

    K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

    \"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

    \"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    A 2022\/2023-as influenzaszezonban (2022. okt\u00f3ber \u2013 2023. m\u00e1jus) Eur\u00f3p\u00e1ban v\u00e9gzett multicentrikus, k\u00f3rh\u00e1zi vizsg\u00e1latunkban az influenza elleni v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get (VE) m\u00e9rt\u00fck a feln\u0151tt lakoss\u00e1g k\u00f6r\u00e9ben. A kutat\u00e1sban k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 18 \u00e9ves \u00e9s id\u0151sebb, feln\u0151tt p\u00e1cienseket vizsg\u00e1ltunk, akik megfeleltek a s\u00falyos, akut l\u00e9g\u00fati megbeteged\u00e9s klinikai krit\u00e9riumainak. Az eset-kontroll elrendez\u00e9s\u0171 vizsg\u00e1latot teszt-negat\u00edv m\u00f3dszerrel v\u00e9gezt\u00fck. Esetnek azokat a betegeket …<\/p>\n","protected":false},"author":102284,"featured_media":2304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2303","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2303"}],"version-history":[{"count":4,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2303\/revisions"}],"predecessor-version":[{"id":2316,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2303\/revisions\/2316"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2304"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}